MiSTIC asthma trial comparing medium-dose Trimbow vs high-dose Foster in uncontrolled asthma with persistent airflow limitation

Phase 4, randomised, double-blind trial of beclometasone dipropionate/formoterol fumarate/glycopyrronium and beclometasone dipropionate + formoterol in asthma (6 arms), sponsored by Chiesi Farmaceutici S.p.A. Primary endpoints: Proportion of subjects exhibiting on average no persistent airflow limitation over 26 weeks and Proportion of subjects with adequately controlled asthma in open-label extension cohorts. Started Jun 2022; status: completed.